All In Biotech

NDA 018227 · Hospira

Amidate

Etomidate · Injection · General Anesthetic

Novel

Last checked: Nov 20, 2026Latest source record: Apr 27, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1982

Sep 7, 1982

Approved uses

1

Original approval plus efficacy supplements

Registered trials

114

8 Phase 3, 10 recruiting

FAERS reports

2,262

2,079 serious, 478 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 22, 2026.

INDICATIONS AND USAGE AMIDATE is indicated by intravenous injection for the induction of general anesthesia. When considering use of AMIDATE, the usefulness of its hemodynamic properties (see CLINICAL PHARMACOLOGY ) should be weighed against the high frequency of transient skeletal muscle movements (see ADVERSE REACTIONS ). Intravenous AMIDATE is also indicated for the supplementation of subpotent anesthetic agents, such as nitrous oxide in oxygen, during maintenance of anesthesia for short operative procedures such as dilation and curettage or cervical conization.

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 7, 1982 Original approval · Type 1 - New Molecular Entity
1 products under this application
  • AMIDATE · ETOMIDATE 2MG/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Etomidate" as an intervention, any sponsor and status, largest first.

All 114 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • renal failure239
  • pain205
  • injury186
  • anxiety181
  • drug ineffective175
  • unevaluable event168
  • hypotension159
  • fear154
  • cardiac arrest148
  • emotional distress144
  • renal injury134
  • renal impairment127

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200460
200528
200639
200732
200847
200942
201072
2011214
2012103
201360
201478
201576
201696
201784
2018106
201987
2020166
2021129
2022123
2023152
2024117
2025195
2026156

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 9, 2026

    Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01). Other

  • Current · updated Nov 9, 2026

    Amidate, Injection, 2 mg/mL (NDC 0409-6695-02).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 619 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.